You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,575,146


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,575,146
Title:Pharmaceutical uses of staurosporine derivatives
Abstract: This application relates to the use of staurosporines derivatives for the curative, palliative or prophylactic treatment of allergic rhinitis, allergic dermatitis, drug allergy or food allergy, angioedema, urticaria, sudden infant death syndrome, bronchopulmonary aspergillosis, multiple sclerosis, or mastocytosis; and to a method of treatment of warm-blooded animals in which a therapeutically effective dose of a compound of a Staurosporine Derivative is administered to a warm-blooded animal suffering from one of the diseases or conditions mentioned above.
Inventor(s): Coutre; Steven (Stanford, CA)
Assignee: Novartis AG (Basel, CH)
Application Number:10/560,669
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,575,146
Patent Claims: 1. A method of treating mastocytosis, which comprises administering a therapeutically effective amount of a compound of formula (VII) ##STR00006## or a pharmaceutically acceptable salt thereof, to a human patient suffering from mastocytosis, wherein the human patient ha KIT tyrosine kinase receptor with a D816V mutation.

2. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the compound is not administered and this cycle being repeated for from 1 to several cycles.

3. A method according to claim 1, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

4. A method according to claim 1, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

5. A method according to claim 1, wherein the compound of formula VII is administered three times a day, for a total dose of 225 mg daily.

6. A method according to claim 1, wherein the compound of formula VII is administered orally.

7. A method according to claim 1, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

8. A method according to claim 1, wherein up to 125 mg per day of the compound of formula VII is administered.

9. A method according to claim 4, wherein the compound of formula VII is administered orally.

10. A method according to claim 9, wherein the compound of formula VII is administered as a microemulsion.

11. A method of treating mastocytosis with resistance to imatinib, which comprises administering a therapeutically effective amount of a compound of formula (VII) ##STR00007## or a pharmaceutically acceptable salt thereof, to a patient suffering from mastocytosis with resistance to imatinib and wherein the patient ha KIT tyrosine kinase receptor with a D816V mutation.

12. A method according to claim 11, wherein the therapeutically effective amount of the compound of formula VII is administered to a mammal subject 7 to 4 times a week or about 100% to about 50% of the days in the time period, for a period of from one to six weeks, followed by a period of one to three weeks, wherein the compound is not administered and this cycle being repeated for from 1 to several cycles.

13. A method according to claim 11, wherein the therapeutically effective amount of the compound of formula VII is 100 to 300 mg daily.

14. A method according to claim 11, wherein the compound of formula VII is administered one, two or three times a day, for a total dose of 100 to 300 mg daily.

15. A method according to claim 11, wherein the compound of formula VII is administered orally.

16. A method according to claim 11, wherein the compound of formula VII is administered as a microemulsion, soft gel or solid dispersion.

17. A method according to claim 11, wherein up to 125 mg per day of the compound of formula VII is administered.

18. A method according to claim 14, wherein the compound of formula VII is administered orally.

19. A method according to claim 18, wherein the compound of formula VII is administered as a microemulsion.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.